Form 4 for AMGN Amgen

Accepted 2021-11-03 00:00:00 ET · period of report 2021-11-02 · accession 0001127602-21-028367 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2021-11-03	2021-11-02	AMGN	REESE DAVID M	EVP, Research, Development	F - Tax	$209.74	-2,192	42.6K	-5%	-$459.8K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-11-02	F	D	2,192	$209.74	42,593	D	—	—	(F1) These shares include the following Restricted Stock Units granted under the Company's equity plans: 345 RSUs which will vest on 4/27/2022; 4,363 RSUs which vest on 11/2/2022; 3,023 RSUs which will vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 880 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.